Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control armsMehmet Burcu, Wei Zhou, Nancy A Dreyer et al.|Pharmacoepidemiology and Drug Safety|2020Cited by 120
Methods for external control groups for single arm trials or <scp>long‐term</scp> uncontrolled extensions to randomized clinical trialsJohn D. Seeger, Jesse A. Berlin, Kourtney J. Davis et al.|Pharmacoepidemiology and Drug Safety|2020Cited by 68
Considerations in characterizing real‐world data relevance and quality for regulatory purposes: A commentaryCynthia J. Girman, Nancy A Dreyer, Mary E. Ritchey et al.|Pharmacoepidemiology and Drug Safety|2018Cited by 40
Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysisNancy A Dreyer, Jonathan Morris, Matthew W. Reynolds et al.|Travel Medicine and Infectious Disease|2020Cited by 28
Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19Nancy A Dreyer, Stephen Toovey, Natalia Petruski‐Ivleva et al.|International Journal of General Medicine|2021Cited by 26